Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

The Relationship Between Myonectin Concentration and the Course of ST-segment Elevation Myocardial Infarction

Assessing the Relationship Between Myonectin Concentration and the Course of Hospitalization and the 30-day Risk of Cardiac Endpoints in Patients With the First Incident of ST-segment Elevation Mycardial Infarction Treated With Primary PCI

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The aim of this study is to test the potentially protective role of myonectin in patients with a first episode of ST elevation myocardial infarction (MI) treated with primary percutaneous coronary intervention (PCI). The main questions which are assumed to be answered after study completion: 1. Does higher myonectin concentration influence the in-hospital and 30-day course of the first ST-elevation MI in patients treated with primary coronary angioplasty 2. Is there a relationship between the serum myonectin concentration, related to patient's nutritional status and physical activity with the patient's physical activity declared as usually before the coronary event occurrence, the cardiac biomarkers level, and myocardial and skeletal muscle mass determined in order to objectify the relationship of physical activity before the infarction with 30-day and one-year mortality, and the other primary and secondary outcomes measured at 12-month visit, e.g. the extent of myocardial infarction, 3. Is there a relationship between the baseline concentration of myonectin and troponin with the control of atherosclerosis risk factors, declared physical activity and parameters of body composition, outcome of treadmill exercise test, values of echocardiographic parameters and myonectin concentration 12 months after a cardiovascular incident

Who May Be Eligible (Plain English)

Who May Qualify: - symptoms of acute coronary syndrome - acute ST segment elevation in two or more leads in ECG - primary PCI Who Should NOT Join This Trial: - pregnancy - patients unconscious, with altered consciousness or not able to cooperate - cardiogenic shock - significant physical effort within 24 hours before onset of MI - active infection at admission, intramuscular injection - myocardial infarction in patient's medical history - heart failure New York Heart Association (NYHA) class III - IV in patient's medical history - renal failure (chronic kidney disease, CKD) with glomerular filtration rate (GFR) \< 30ml/min - history of malignant neoplasms in the last 5 years - patients incapacitated, active soldiers, imprisoned or related with investigators Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * symptoms of acute coronary syndrome * acute ST segment elevation in two or more leads in ECG * primary PCI Exclusion Criteria: * pregnancy * patients unconscious, with altered consciousness or not able to cooperate * cardiogenic shock * significant physical effort within 24 hours before onset of MI * active infection at admission, intramuscular injection * myocardial infarction in patient's medical history * heart failure New York Heart Association (NYHA) class III - IV in patient's medical history * renal failure (chronic kidney disease, CKD) with glomerular filtration rate (GFR) \< 30ml/min * history of malignant neoplasms in the last 5 years * patients incapacitated, active soldiers, imprisoned or related with investigators

Locations (1)

Voivodeship Hospital in Elblag
Elblag, Warmian-Masurian Voivodeship, Poland